Search

Yasmin Khakoo is a pediatric neurologist and neuro-oncologist who directs the Child Neurology Program at MSK Kids.

… Thursday, June 17, 2021 VIDEO | 02:31 Meet MSK Kids Pediatric Neurologist & Neuro-Oncologist Yasmin Khakoo Yasmin Khakoo is the Director of the MSK Kids Child Neurology Program. Learn about her expertise in caring for children and young adults with primary brain tumors. Video Details Yasmin Khakoo is

Meet Anna, who underwent care for breast cancer at Memorial Sloan Kettering and documented the experience in photos.

… Tuesday, May 7, 2019 Memorial Sloan Kettering breast cancer patient Anna Rathkopf Anna Rathkopf took self-portraits as a way to use her creativity during cancer treatment. Asha blowing bubbles at last treatment From left: Anna and nurses Asha Monge and Betsy Berdelle celebrate on Anna's last day of treatment

American Thyroid Association guidelines endorse close observation as a treatment option for many small papillary thyroid tumors rather than surgery. MSK endocrinologist Michael Tuttle MD discusses why monitoring such cancers is a viable approach.

… Thursday, August 31, 2017 VIDEO | 02:27 Active Monitoring of Papillary Thyroid Cancer American Thyroid Association guidelines endorse close observation as a treatment option for many small papillary thyroid tumors rather than surgery. MSK endocrinologist Michael Tuttle MD discusses why monitoring such

Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved by the FDA, thanks to a clinical trial co-led by MSK.

… Thursday, November 21, 2024 On November 20, 2024, the U.S. Food and Drug Administration granted accelerated approval to the drug zanidatamab (Ziihera ® ) to treat advanced and metastatic bile duct cancer (cholangiocarcinoma) and other biliary tract cancers that have high levels of a protein called HER2

Since its founding 19 years ago, the Gerstner Sloan Kettering Graduate School of Biomedical Sciences has attracted bright minds drawn to its connection to MSK. Learn more about how we're training tomorrow's leaders.

… Wednesday, November 12, 2025 It’s that time of year, when aspiring scientists across the nation and the world are deciding where to pursue their doctoral degrees in biomedical research. The competition is intense, and the decision is a major life commitment. The PhD, or Doctorate of Philosophy, is the

Memorial Sloan Kettering has convened a COVID-19 Operating Room Executive Committee to scrutinize all surgical cases and determine whether they were truly essential and to review needs, resources, and ICU availability.

… Monday, May 11, 2020 The COVID-19 pandemic has stressed healthcare systems globally and is presenting particular challenges to cancer surgeons and cancer surgery programs. As New York City quickly became the epicenter of the pandemic in the United States, Memorial Sloan Kettering convened an Operating

An MSK medical oncologist and geneticist discusses the latest drug approved for breast cancer and how genetic testing can lead to new treatments.

… Wednesday, February 21, 2018 Summary In this interview, Mark Robson, Chief of the Breast Medicine Service at Memorial Sloan Kettering, discusses olaparib, the latest drug approved for breast cancer, and how genetic testing can lead to new targeted therapies. Last month, the US Food and Drug Administration

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that they will expand the focus of the successful Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a partnership established in 2013 to expedite early-stage drug discovery of innovative new therapies. Under this expansion, Tri-I TDI will extend its current relationship with its industry partner, Takeda Pharmaceutical Company, Ltd. from the realm of small molecule discovery into the new research area of antibody drug discovery. All three institutions will benefit from Tri-I TDI’s expansion.

… Thursday, June 16, 2016 Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that they will expand the focus of the successful Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a partnership established in 2013 to expedite

Read about a CAR T cell therapy that appears effective against light chain (AL) amyloidosis.

… Sunday, December 7, 2025 VIDEO | 02:47 Watch How CAR T Cell Therapy Eliminated a Patient’s Rare Blood Disease Every cancer breakthrough begins years before it offers patients new hope. Our series Saved by Science takes you inside MSK’s world class research labs, where you’ll see patients meet the scientists

The scientific world lost one of its greats this week. Here, we reflect on his influence.

… Friday, January 11, 2019 John Mendelsohn John Mendelsohn John Mendelsohn Dr. Mendelsohn in his lab at MSK John Mendelshon Dr. Mendelsohn in his lab at MSK Summary Former MSK physician-scientist John Mendelsohn, who served the institution in multiple roles from 1985 to 1996, died on January 7 from brain